Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

Study Identifier
150998-006
CT.gov Identifier
EudraCT Identifier
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Results Available

Statistical Analysis Plan
Available Language(s): English
Protocol
Available Language(s): English

Study Details

Medical Condition
  • Macular Degeneration - Other
  • Study Drug
  • Abicipar Pegol
  • Ranibizumab
  • Phase
    Phase 3
    Sex
    Female & Male
    Age
    50+ years

    Protocol Summary

    This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.

    Study Locations

    Location
    Status
    Location
    Eye Foundation Hospital
    Birmingham, Alabama, United States, 35233
    Status
    Not applicable
    Location
    Retinal Consultants of Arizona
    Gilbert, Arizona, United States, 85296
    Status
    Not applicable
    Location
    Barnet Dulaney Perkins Eye Center - Phoenix
    Phoenix, Arizona, United States, 85016-4701
    Status
    Not applicable
    Location
    Retina Centers, PC
    Tucson, Arizona, United States, 85704
    Status
    Not applicable
    Location
    Northwest Arkansas Retina Associates
    Springdale, Arkansas, United States, 72762
    Status
    Not applicable
    Location
    Win Retina
    Arcadia, California, United States, 91006
    Status
    Not applicable
    Showing {first} - {last} of {total} Results